Swiss Auto Components Stock News

Lonza Group (SWX:LONN) has moved into focus after joining a funded research collaboration with Simulations Plus and the U.S. Food and Drug Administration to build predictive frameworks for amorphous solid dispersion drug products. See our latest analysis for Lonza Group. Despite the new FDA-backed collaboration and recent conference appearances, Lonza Group’s 1-day share price return of 1.83% comes against a weaker backdrop. The 90-day share price return of 12.5% and the 1-year total...

Aevis Victoria (SWX:AEVS) has drawn investor attention after shareholders approved a CHF 3.45 per share payout for 2025, signalled expectations for a higher 2026 dividend, and elected two new board members. See our latest analysis for Aevis Victoria. The recent shareholder meeting news comes after a steady share price context, with a CHF 13.70 last close, a 3.40% year to date share price return and a 5 year total shareholder return of 11.07%, while the 3 year total shareholder return decline...

Temenos AG ( VTX:TEMN ) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders...

Sika (SWX:SIKA) is back in focus after announcing a new national subsidiary in Kyrgyzstan, taking its network to 103 countries and expanding its reach into Central Asia’s construction market. See our latest analysis for Sika. The Kyrgyzstan move comes after Sika reaffirmed its 2026 sales growth guidance earlier in April. It also lands at a time when the CHF145.35 share price sits against a 30 day share price return of 13.11% but a 1 year total shareholder return of 27.43% decline, suggesting...

Novartis (SWX:NOVN) has received European Commission approval for Rhapsido, the first oral targeted treatment for chronic spontaneous urticaria (CSU). The approval provides a new option for CSU patients in Europe whose symptoms are not controlled with antihistamines. Rhapsido is positioned as an oral therapy that does not require lab monitoring, aimed at simplifying treatment for eligible patients. For a company already focused on immunology and dermatology, Rhapsido adds another...

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index experiencing a decline and major indices like Germany's DAX and France's CAC 40 also seeing significant drops, amid geopolitical tensions and economic uncertainties. Despite these hurdles, high-growth tech stocks in Europe continue to attract attention as investors look for companies that can navigate current market volatility by leveraging innovation, robust business models, and strong growth...

Wondering if ABB, at a last close of CHF 77.90, still offers value after such a strong run, or if you are arriving late to the story. The share price performance has been strong, with returns of 3.2% over 7 days, 23.4% over 30 days, 27.2% year to date, 82.8% over 1 year, 156.1% over 3 years and 207.8% over 5 years. This naturally raises questions about risk and upside from here. Recent coverage has focused on ABB's position in electrification, automation and power grid technology, which ties...

Why Holcim’s Q1 update matters for shareholders Holcim (SWX:HOLN) opened 2026 with an 8.3% rise in recurring EBIT, as its Q1 sales and trading statement highlighted firm demand for sustainable building materials and pricing actions. The company also reiterated profit growth guidance despite Swiss franc currency pressure. See our latest analysis for Holcim. Holcim’s Q1 update comes after a mixed share price pattern, with a 12.1% 1 month share price return but a 6.8% decline year to date, while...

Nestlé reported past first-quarter 2026 group sales of CHF 21,317 million, down from CHF 22,601 million a year earlier, while organic growth and volumes improved despite an infant formula recall and currency headwinds. At the same time, the company accelerated portfolio streamlining and cost-saving efforts, including European job cuts and potential further ice cream divestments, highlighting a sharper focus on efficiency and core categories like coffee, pet care and nutrition. We’ll now...

Schindler Holding AG ( VTX:SCHN ) came out with its first-quarter results last week, and we wanted to see how the...

UBS Group (SWX:UBSG) is challenging new Swiss capital rules that it describes as extreme and harmful for the Swiss economy. The Swiss government has finalized capital adequacy requirements that would add significant capital demands on UBS, including 100% capital backing for foreign units at the parent level. UBS has publicly opposed these measures, arguing they are not aligned with international standards and could affect the bank's global operations. UBS is one of the largest global wealth...

If you are wondering whether Amrize at around CHF44.64 is priced attractively or not, the key question is how its current share price compares with its underlying business value. Recently, the stock has been relatively steady, with a 1.1% return over the last 30 days and a 3.0% decline over the last 7 days. This may reflect shifting views on its near term prospects and risk. Recent news flow on Amrize has focused more on maintaining investor visibility than on any single transformational...

When companies post strong earnings, the stock generally performs well, just like Burkhalter Holding AG's ( VTX:BRKN...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Nestlé (SWX:NESN) is back in focus after first quarter sales exceeded expectations, supported by 3.5% organic growth across categories like coffee and snacks, while management reaffirmed its full year outlook despite currency and recall headwinds. See our latest analysis for Nestlé. The recent first quarter beat and portfolio reshaping, including the planned Blue Bottle Coffee sale and potential ice cream exit, have supported a 90 day share price return of 12.01%. This comes even as the 1...

Cosmo (SWX:COPN) is back in focus after reporting 12 month Phase III results for its Clascoterone 5% topical solution in male androgenetic alopecia, highlighting long term safety, ongoing efficacy and preparation for global regulatory filings. See our latest analysis for Cosmo. The latest clinical update comes after a mixed period in the market, with a 23.6% 1 month share price return and a 16.99% 3 month decline. Meanwhile, the 1 year total shareholder return sits at 111.93%, suggesting...

Wondering if Roche Holding at around CHF324.90 is offering fair value or if the price is running ahead of the story? This article focuses squarely on what that share price may or may not reflect. Over the past week the stock returned 3.6% and over the last month 6.2%. The 1 year return stands at 27.7%, and the year to date move is close to flat at a 0.2% decline. Recent news flow around Roche Holding has kept attention on the stock, from ongoing discussion of its position in global...

Readers hoping to buy Walliser Kantonalbank ( VTX:WKBN ) for its dividend will need to make their move shortly, as the...

ABB launched its HiPerGuard 34.5kV medium voltage UPS for AI data centers, enabling direct-to-grid power connections. The system is microgrid ready and is the first in its class to receive UL 9540 certification for safety and performance. ABB reported record order intake and cash flow alongside this product launch, highlighting strong operating momentum. ABB (SWX:ABBN) is drawing attention with this data center focused UPS launch while its shares trade around CHF78.1. The stock has...

As European markets experience a positive upswing, highlighted by gains in major indices like Germany’s DAX and France’s CAC 40, investors are closely monitoring the region's economic outlook amid geopolitical developments. In this environment, growth companies with substantial insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business operations.

Temenos AG ( VTX:TEMN ) just released its quarterly report and things are looking bullish. Temenos beat earnings, with...

Schindler Holding (SWX:SCHN) has opened Q1 2026 earnings season with a clean set of headline numbers, coming off Q4 2025 revenue of CHF 2.8b and basic EPS of CHF 2.46, supported by trailing 12 month revenue of CHF 11.0b and EPS of CHF 9.48 as earnings grew 6.8% over the past year. Over recent quarters the company has seen revenue move within a CHF 2.7b to CHF 2.9b range while quarterly EPS has held between CHF 2.16 and CHF 2.46, which points to a business that is leaning on steady...

Some investors may be wondering whether Novartis at around CHF116 per share is still good value, or if most of the opportunity is already reflected in the price. The stock has had a 1% decline over the past week and past month, while posting returns of 7.2% year to date and 30.2% over the last year. This may catch the eye of investors weighing reward against risk. Recent headlines have highlighted Novartis as a large, established player in global pharmaceuticals. This keeps it on the radar...

Wondering whether UBS Group at around CHF33.54 is still good value or starting to look stretched? This overview is built to help you frame that question clearly. The stock has had mixed recent performance, with a 0.9% decline over the last 7 days, a 14.0% gain over the last 30 days, a 12.1% decline year to date, and a 42.1% return over the last year, alongside multi year returns of 102.9% over 3 years and 172.7% over 5 years. Recent coverage of UBS Group has focused on its position as a...